5 Surprising Signs of Aging
Jancee Dunn / nytimes - Hint: You may need to buy new shoes.
AI Summary: Phase III DESTINY‑Lung04 data show trastuzumab deruxtecan (Enhertu) significantly prolongs progression‑free survival as first‑line therapy for HER2‑mutant non‑small cell lung cancer. Investigators hail the efficacy signal, but oncologists caution that longer follow‑up is needed to determine whether the PFS benefit will translate into overall survival advantage.
Ex-Fauci adviser pleads guilty to plotting to conceal COVID-19 research records
abcnews - A former senior adviser to infectious disease expert Dr. Anthony Fauci has pleaded guilty to plotting to conceal federal records related to research on the origins of the deadly COVID-19 pandemic
AI Summary: A former scientific adviser to Dr. Fauci pleaded guilty to attempting to conceal COVID‑19 research records, admitting to actions to withhold or obscure documentation related to pandemic studies. The plea resolves part of a wider investigation into recordkeeping and transparency, and underscores legal exposure when internal scientific communications collide with public scrutiny.
Charles Roberts Named the Next President and CEO of St. Jude Children’s Research Hospital
oncodaily - Charles Roberts, Current Cancer Center Director and Executive Vice-President and Next President and CEO of St. Jude Children’s Research Hospital, shared St. Jude Children’s Research Hospital’s post on LinkedIn, adding: […]
AI Summary: Charles Roberts was named president and CEO of St. Jude Children’s Research Hospital, stepping into leadership of a globally recognized pediatric cancer and research institution. He’ll oversee strategy, fundraising and clinical priorities as the center pursues ambitious research and care goals — and deal with the inevitable complexity of running a world-class nonprofit hospital.
AI may know how you’ll respond to a vaccine before you get it
sciencedaily - AI may be able to predict how strongly someone will respond to a vaccine before they receive it. By analyzing antibody patterns in more than 4,000 people, researchers found signs of “immune readiness” that helped distinguish strong responders from weak on…
AI Summary: Researchers report AI models that can forecast individual immune responses to vaccines by identifying predictive biological signatures. These tools could enable personalized vaccination strategies and smarter trial design, although real‑world validation and ethical deployment remain necessary before clinics trade one‑size‑fits‑all jabs for algorithmic matchmaking.
FDA Lists More Than 1,500 AI-Enabled Medical Devices as Oncology Applications Expand
oncodaily - The U.S. Food and Drug Administration (FDA) has listed more than 1,500 artificial intelligence-enabled medical devices authorized for marketing in the United States, reflecting the growing integration of AI across […]
AI Summary: The FDA catalogued more than 1,500 AI‑enabled medical devices, spurring criticism that most were cleared without direct evidence they improve patient outcomes. Regulators and clinicians face mounting calls for post‑market studies and transparency, balancing enthusiasm for AI innovation against the sober question: do these devices actually help patients?
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Frank Vinluan / medcitynews - Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post …
AI Summary: Ultragenyx received FDA approval for a gene therapy, marking the first approved treatment for that particular ultra‑rare disorder. The decision provides a regulated therapeutic option for patients previously without approved care, highlighting the evolving regulatory willingness to greenlight transformative but small‑population medicines.
ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC
oncodaily - Treatment intensification with androgen receptor pathway inhibitors has become central to the management of metastatic hormone-sensitive prostate cancer (mHSPC). However, as patients remain on these therapies for years, longer follow-up […]
AI Summary: Long-term follow-up from ENZAMET shows enzalutamide continues to deliver a substantial overall survival benefit at eight years for patients with metastatic hormone-sensitive prostate cancer. The durable outcome cements enzalutamide’s role in combination androgen-deprivation strategies, giving patients and clinicians a proven option — not a cure, but progress that actually lasts.
Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
oncodaily - Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial, evaluating intismeran autogene (V940/mRNA-4157) plus Keytruda (pembrolizumab) as adjuvant treatment for patients with completely resected stage IIB-IV […]
AI Summary: Merck and Moderna announced that their mRNA-based melanoma vaccine, given with Keytruda, met key phase‑3 endpoints — reducing recurrence and distant metastasis after resection. The data suggest the vaccine can prime anti‑tumor immunity to prevent relapse, positioning it as a potential adjunct to standard checkpoint inhibition in high‑risk patients.
- Experts weigh in on personalized mRNA cancer vaccines (4)
- INTerpath-001: phase‑3 vaccine reduces melanoma recurrence (6)
- Market surge: Moderna's stock jumps after trial news (3)
- All Other Stories
Experts weigh in on personalized mRNA cancer vaccines
INTerpath-001: phase‑3 vaccine reduces melanoma recurrence
Market surge: Moderna's stock jumps after trial news
All Other Stories
Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors
esmo - Findings from the LITESPARK-011 study
AI Summary: A Phase 3 trial shows belzutifan combined with lenvatinib improves progression-free survival compared with cabozantinib in patients with advanced renal cell carcinoma who progressed on PD‑1/PD‑L1 inhibitors. The result offers a new sequenced treatment option and shifts the landscape for post–checkpoint inhibitor RCC management.
A simple blood test could detect multiple cancers and reveal where they started
sciencedaily - UCLA researchers have created a blood test that can scan DNA signals for multiple cancers, liver diseases, and signs of organ damage—and even indicate where trouble may be developing. Early results suggest the inexpensive approach could bring medicine clo…
AI Summary: Researchers report a blood test capable of detecting multiple cancer types and indicating their tissue of origin, offering a potential multi‑cancer early‑detection tool. While sensitivity, specificity and real‑world performance remain under evaluation, the approach could shift screening paradigms if validated across diverse populations and clinical settings.
Anas Younes: Decade-Long Persistence of CD19 CAR T Cells in B Cell Lymphomas
oncodaily - Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared on LinkedIn: “While these findings demonstrate that CART19 cells can persist for more than 10 years in […]
AI Summary: Long-term follow-up shows CD19-directed CAR‑T cells can persist for a decade in patients with B‑cell lymphomas, associating with sustained remissions and reshaping expectations about durability, retreatment and long-term toxicity. These findings prompt rethinking of follow-up care and suggest cellular therapies may offer far longer benefits than anyone dared hope.
ASTRO updates guideline on radiation therapy for pancreatic cancer
medicalxpress - An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.
AI Summary: ASTRO released updated 2026 guidance for radiation therapy in pancreatic cancer, refining target volumes, dose constraints, and technique recommendations. The update aims to standardize practice, improve safety for nearby organs at risk, and incorporate emerging evidence on hypofractionation and concurrent systemic therapies to better balance local control with toxicity.
Wungki Park: First Map of Acquired Resistance to Daraxonrasib in Pancreatic Cancer
oncodaily - Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in […]
AI Summary: Researchers have charted acquired resistance mechanisms to the RAS(ON) inhibitor daraxonrasib in pancreatic cancer, identifying pathways that suggest rational combination therapies. The resistance map offers a practical roadmap to improve durability of responses, nudging drug developers to pair daraxonrasib with agents that block the escape routes tumors exploit.
Study ties estrogen-based menopausal hormone therapy to lower Alzheimer's risk
medicalxpress - Women on regimens of estrogen-only menopausal hormone therapy are at reduced risk of Alzheimer's disease, a study by Stanford Medicine investigators has found. Because estrogen-only therapy is generally prescribed for women without a uterus, most of these…
AI Summary: Observational research linked estrogen‑based menopausal hormone therapy to fewer Alzheimer’s‑related brain changes on imaging, suggesting a potential protective association. Investigators stress that timing, confounding factors and observational design limit causal claims, so randomized trials and careful risk‑benefit assessment remain necessary before changing clinical practice — or anyone swapping kale for HRT on a whim.
A surprising triple treatment completely clears hiv in newborn primates
sciencedaily - Researchers have found a striking new way to potentially eliminate HIV soon after infection using a one-time combination of three therapies. In newborn nonhuman primates treated within three days of exposure, the regimen—standard antiretroviral drugs, bro…
AI Summary: A preclinical study reports that a triple‑dose therapeutic regimen eradicated detectable HIV in newborn primates, offering proof‑of‑concept that very early, intensive intervention might prevent persistent infection. Translation to human infants will require careful clinical trials, ethical oversight and long follow‑up, but the findings mark a hopeful, if cautious, step toward functional cures.
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
oncodaily - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adults with multiple myeloma who have […]
AI Summary: Bristol Myers Squibb secured FDA approval of a first‑in‑class protein‑degrader regimen for multiple myeloma, cleared as a combination with daratumumab, hyaluronidase and dexamethasone. The nod marks a notable shift toward targeted degrader strategies in hematologic oncology and gives clinicians another option for patients with advanced disease.
FDA advisers to weigh cancer blood test
Ella Jeffries / beckershospitalreview - The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet Sept. 23 to discuss and vote on Grail’s premarket approval application for its Galleri blood test, according to a notice published Aug. 10 in the Federal R…
AI Summary: FDA advisors are set to review a multi-cancer early-detection blood test, weighing evidence on accuracy, clinical utility, and how to handle follow-up diagnostics. Regulators must decide whether the test meets approval standards for broad screening, balancing potential earlier cancer detection against risks of false positives, overdiagnosis, and costly downstream workups.
Fridge-free tetanus-diphtheria vaccine shows promise of reaching millions worldwide
medicalxpress - The encouraging results of the world's first trial of a fridge-free tetanus-diphtheria vaccine could improve access worldwide to crucial treatments while reducing carbon emissions. Fridge-free vaccines have the potential to transform vaccine delivery by r…
AI Summary: Early studies of fridge‑free vaccine formulations, including a tetanus‑diphtheria candidate, indicate stability without cold storage, promising to reduce discarded doses and simplify distribution in low‑resource settings. If these results hold up, the change could shrink logistical headaches, boost global immunization reach and finally make the vaccine refrigerator’s light a little less terrifying.
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)
Access, dose optimization and real-world data for Lu-177
FDA expands Pluvicto approval; industry reaction
PSMAddition trial: earlier Lu-177 delays metastatic progression
Mel Mann Highlights First Patient Enrollment in AACR-ADOPT-GEA Trial
oncodaily - Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) […]
AI Summary: The AACR‑affiliated ADOPT‑GEA phase II trial for locally advanced gastroesophageal cancer has reported its first patient enrollment, marking a key milestone in the study's launch. The enrollment signals trial readiness and opens recruitment momentum to evaluate investigational approaches for a challenging cancer subtype, advancing potential new treatment options toward evidence‑based use.